A real-world, observational study of erenumab for migraine prevention in Canadian patients.

ABSTRACT:

Objectives

To assess real-world effectiveness, safety, and usage of erenumab in Canadian patients with episodic and chronic migraine with prior ineffective prophylactic treatments.

Background

In randomized controlled trials, erenumab demonstrated efficacy for migraine prevention in patients with ≤4 prior ineffective prophylactic migraine therapies. The "Migraine prevention with AimoviG: Informative Canadian real-world study" (MAGIC) assessed real-world effectiveness of erenumab in Canadian patients with migraine.

Methods

MAGIC was a prospective open-label, observational study conducted in Canadian patients with chronic migraine (CM) and episodic migraine (EM) with two to six categories of prior ineffective prophylactic therapies. Participants were administered 70 mg o

SUBMITTER: Becker WJ 

PROVIDER: S-EPMC9320807 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature